Randomised phase II study of hepatic arterial infusion with floxuridine and dexamethasone with IV [intravenous] systemic chemotherapy with and without bevacisumab (mab to vascular endothelial growth factor-A) in patients with resected hepatic metastases from colorectal cancer.

Trial Profile

Randomised phase II study of hepatic arterial infusion with floxuridine and dexamethasone with IV [intravenous] systemic chemotherapy with and without bevacisumab (mab to vascular endothelial growth factor-A) in patients with resected hepatic metastases from colorectal cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Dexamethasone; Floxuridine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 29 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top